Status:
TERMINATED
Cerebral Impact of Cognitive Remediation for People Suffering From Schizophrenia
Lead Sponsor:
Hôpital le Vinatier
Conditions:
Schizophrenia
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
Neurocognitive deficits are frequent with people suffering from schizophrenia. Unlike positive symptoms, cognitive deficits are not reduced with antipsychotic medication. They can be very disabling, e...
Detailed Description
Among cognitive deficits associated to schizophrenia, the jumping to conclusion bias is a frequent consequence of the decision making process alteration. This bias is characterized by a fast decision ...
Eligibility Criteria
Inclusion
- People suffering from schizophrenia given the DSM-5
- People aged from 18 to 45 years old
- French mother tongue
- Medicated with Aripiprazole
- Medication unchanged in the last month
- Stable symptomatology
- People consenting to the research.
Exclusion
- Recent addiction (tabacco excluded)
- Neurologic disorders (vascular disorders, neurodegenerative disorders, infections…)
- Somatic medication having cerebral impact (such as corticoids)
- Pregnant women, guardianship people.
Key Trial Info
Start Date :
December 17 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 17 2023
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT04033978
Start Date
December 17 2019
End Date
June 17 2023
Last Update
February 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
centre de réhabilitation - Hôpital le Vinatier
Lyon, Rhône, France, 69006